This is the authors' abstract. We don't add key points for this paper.
The recent cloning of the thrombopoietin gene, and the production of recombinant protein, have allowed studies on both its biological actions and clinical utility. Thrombopoietin not only affects the cells of the megakaryocytic lineage, but has a diverse set of cellular targets. In particular, it stimulates the ex vivo expansion of hematopoietic stem/progenitor cells suggesting that it may play a role in transplantation studies. Pre-clinical but limited clinical studies indicate that under defined conditions, thrombopoietin may accelerate white blood cell count and platelet recoveries following myelosuppression or radiotherapy.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Michael W. Long (1999) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: